Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotechnology company focused on developing curative therapies for heart disease, has announced its participation in two major investor conferences in March 2025.
The company will be featured at:
- TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, with a company presentation from 1:10 PM ET to 1:40 PM ET
- Leerink Partners Global Healthcare Conference 2025 on Wednesday, March 12, participating in a fireside chat from 8:40 AM ET to 9:10 AM ET
CEO Faraz Ali will represent the company at both events. Live and archived webcasts will be available through Tenaya's website Investors section, with replays accessible for approximately 30 days after each conference.
Positive
- None.
Negative
- None.
News Market Reaction – TNYA
In the trading session that priced this news, TNYA declined 6.25%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows:
TD Cowen 45th Annual Health Care Conference
Date: Tuesday, March 4
Time: 1:10 PM ET – 1:40 PM ET
Format: Company Presentation
Leerink Partners Global Healthcare Conference 2025
Date: Wednesday, March 12
Time: 8:40 AM ET – 9:10 AM ET
Format: Fireside Chat
The live and archived webcast of the presentation and fireside chat may be accessed from the Investors section of Tenaya’s website. A replay of the webcasts will be available on the Tenaya website for approximately 30 days following each conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
